TRBV4-1: A Non-Code RNA Molecule as A Drug Target and Biomarker

Target Name: TRBV4-1

NCBI ID: G28617

TRBV4-1

Other Name(s): TCRBV4S1 | TCRBV7S1A1N2T | BV07S1J2.7 | TRBV41 | T cell receptor beta variable 4-1

TRBV4-1: A Non-Code RNA Molecule as A Drug Target and Biomarker

TRBV4-1 (TcRBV4S1) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and function have made it an attractive target for researchers to study, and its potential as a drug may have significant implications for the treatment of certain diseases.

TRBV4-1 is a RNA molecule that is expressed in various tissues and cells throughout the body. It is a key regulator of gene expression and has been shown to play a role in the development and progression of several diseases, including cancer. Its function is primarily due to its ability to interact with other proteins and molecules, which allows it to regulate gene expression and contribute to the development of certain diseases.

One of the key features of TRBV4-1 is its unique structure. It is a small RNA molecule that is composed of only 19 amino acids. Despite its small size, TRBV4-1 is able to interact with other proteins and molecules and has been shown to play a role in the regulation of gene expression. Its structure allows it to interact with other molecules and participate in various signaling pathways that are involved in disease development.

TRBV4-1 has also been shown to be involved in the regulation of cell cycle progression. It has been shown to interact with the protein known as p21, which is a key regulator of the cell cycle. When TRBV4-1 is expressed in cells, it can interact with p21 and prevent it from binding to the DNA, which can lead to the inhibition of cell cycle progression and the regulation of gene expression.

Another function of TRBV4-1 is its ability to interact with the protein known as NF-kappa-B. NF-kappa-B is a protein that is involved in the regulation of various cellular processes, including inflammation and cancer. TRBV4-1 has been shown to interact with NF-kappa-B and contribute to the regulation of gene expression that is associated with NF-kappa-B signaling.

In addition to its involvement in the regulation of gene expression, TRBV4-1 has also been shown to be involved in the regulation of protein levels in the body. It has been shown to interact with the protein known as SIRT1, which is a gene that is involved in the regulation of protein levels. When TRBV4-1 is expressed in cells, it can interact with SIRT1 and contribute to the regulation of protein levels, which can lead to the inhibition of protein synthesis and the regulation of gene expression.

TRBV4-1 has also been shown to be involved in the regulation of cellular processes that are involved in the development of cancer. It has been shown to interact with the protein known as TP53, which is a key regulator of the DNA damage response. When TRBV4-1 is expressed in cells, it can interact with TP53 and contribute to the regulation of the DNA damage response, which is involved in the development of cancer.

Given its unique structure and function, TRBV4-1 has potential as a drug target and biomarker. Its ability to interact with other proteins and molecules makes it an attractive target for researchers to study and develop new treatments for various diseases, including cancer. Additionally, its potential as a biomarker for disease diagnosis and monitoring may have significant implications for the development of new diagnostic tests for various diseases.

In conclusion, TRBV4-1 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and function have made it an attractive target for researchers to study, and its potential as a drug may have significant implications for the treatment of certain diseases. Further research is needed to fully understand its role in the regulation of gene expression and its potential as a drug

Protein Name: T Cell Receptor Beta Variable 4-1

Functions: V region of the variable domain of T cell receptor (TR) beta chain that participates in the antigen recognition (PubMed:24600447). Alpha-beta T cell receptors are antigen specific receptors which are essential to the immune response and are present on the cell surface of T lymphocytes. Recognize peptide-major histocompatibility (MH) (pMH) complexes that are displayed by antigen presenting cells (APC), a prerequisite for efficient T cell adaptive immunity against pathogens (PubMed:25493333). Binding of alpha-beta TR to pMH complex initiates TR-CD3 clustering on the cell surface and intracellular activation of LCK that phosphorylates the ITAM motifs of CD3G, CD3D, CD3E and CD247 enabling the recruitment of ZAP70. In turn ZAP70 phosphorylates LAT, which recruits numerous signaling molecules to form the LAT signalosome. The LAT signalosome propagates signal branching to three major signaling pathways, the calcium, the mitogen-activated protein kinase (MAPK) kinase and the nuclear factor NF-kappa-B (NF-kB) pathways, leading to the mobilization of transcription factors that are critical for gene expression and essential for T cell growth and differentiation (PubMed:23524462). The T cell repertoire is generated in the thymus, by V-(D)-J rearrangement. This repertoire is then shaped by intrathymic selection events to generate a peripheral T cell pool of self-MH restricted, non-autoaggressive T cells. Post-thymic interaction of alpha-beta TR with the pMH complexes shapes TR structural and functional avidity (PubMed:15040585)

The "TRBV4-1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRBV4-1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets